Ocumension Therapeutics (HKSE:01477) FCF Margin % : -133.64% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ocumension Therapeutics's Free Cash Flow for the six months ended in Jun. 2024 was HK$-241.2 Mil. Ocumension Therapeutics's Revenue for the six months ended in Jun. 2024 was HK$180.5 Mil. Therefore, Ocumension Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was -133.64%.

As of today, Ocumension Therapeutics's current FCF Yield % is -12.70%.

The historical rank and industry rank for Ocumension Therapeutics's FCF Margin % or its related term are showing as below:

HKSE:01477' s FCF Margin % Range Over the Past 10 Years
Min: -57406.16 Med: -1534.67 Max: -150.52
Current: -150.52

During the past 6 years, the highest FCF Margin % of Ocumension Therapeutics was -150.52%. The lowest was -57406.16%. And the median was -1534.67%.

HKSE:01477's FCF Margin % is ranked worse than
51.08% of 1016 companies
in the Biotechnology industry
Industry Median: -140.87 vs HKSE:01477: -150.52

Ocumension Therapeutics FCF Margin % Historical Data

The historical data trend for Ocumension Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics FCF Margin % Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-57,406.16

-3,949.27

-1,534.67

-321.26

-219.10

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial							-414.28	-272.67	-286.59	-170.05	-133.64

Competitive Comparison of Ocumension Therapeutics's FCF Margin %

For the Biotechnology subindustry, Ocumension Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocumension Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Ocumension Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ocumension Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-590.415	/	269.471
	=	-219.10 %

Ocumension Therapeutics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-241.15	/	180.453
	=	-133.64 %

Ocumension Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

https://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Liu Ye	2101 Beneficial owner
6 Dimensions Capital, L.p.	2101 Beneficial owner
Zhang Qiping	2201 Interest of corporation controlled by you
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Boyu Capital Fund Iv, L.p.	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
Alcon Pharmaceuticals Ltd	2101 Beneficial owner
Alcon Inc.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

Ocumension Therapeutics Headlines

No Headlines